Topic: monoclonal antibody
Third Rock startup Goldfinch plans to file an IND for its treatment for rare and metabolic kidney diseases in the second half of next year.
The deal sees Gilead Sciences task AbCellera with using technologies to find rare antibodies with certain characteristics.
Another day, another biopharma veteran hits the exit and walks straight into the arms of Vivek Ramaswamy.
BioNTech has bought up MabVax Therapeutics’ cancer drug assets alongside much of its infrastructure and labs.
AgomAb Therapeutics is coming out of stealth with €21 million to develop agonistic monoclonal antibodies that could potentially treat a range of diseases.
University of Tennessee scientists have designed a CD19-targeting CAR-T for lupus and have shown encouraging results in a mouse study.
Purdue Pharma’s new R&D subsidiary, Imbrium Therapeutics, tapped TetraGenetics and its antibody discovery platform for non-opioid-based painkillers.
Aro Biotherapeutics raised $13 million to build its team and advance its centyrin pipeline, which includes a candidate for non-small cell lung cancer.
HiFiBiO Therapeutics has had a busy year, as pacts and raises abound, and it’s showing no signs of slowing down as it gets its checkbook out for an unusual French spinout.
A phase 2 study of Xencor’s lead antibody missed its primary endpoint in lupus, though the company described the data as worthy of future study.